Ignite Creation Date:
2025-12-24 @ 4:22 PM
Ignite Modification Date:
2026-01-04 @ 5:32 AM
Study NCT ID:
NCT03340766
Status:
COMPLETED
Last Update Posted:
2024-10-17
First Post:
2017-10-23
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Study Investigating the Safety and Efficacy of Blinatumomab in Combination With Pembrolizumab in Adults With Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)
Sponsor:
Amgen
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2018-03-16
Start Date Type:
ACTUAL
Primary Completion Date:
2020-11-06
Primary Completion Date Type:
ACTUAL
Completion Date:
2023-08-14
Completion Date Type:
ACTUAL
First Submit Date:
2017-10-23
First Submit QC Date:
None
Study First Post Date:
2017-11-14
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2021-10-15
Results First Submit QC Date:
None
Results First Post Date:
2022-02-25
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-07-24
Last Update Post Date:
2024-10-17
Last Update Post Date Type:
ACTUAL